A phase 3, randomized, double-blind, fixed-dose, parallel group comparison of controlled-release hydromorphone HCI vs placebo in subjects with osteoarthritis
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2013
At a glance
- Drugs Hydromorphone (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors ALZA Corporation
- 14 Jul 2009 Actual patient number (990) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Actual end date May 2005 added as reported by ClinicalTrials.gov.
- 18 Mar 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.